With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
A new perspective proposes a conceptual framework organizing recursive identity updating and symbolic processing during ...
Automated reaction synthesis supports precise, reproducible high-throughput experimentation while increasing efficiency ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
SALT LAKE CITY, Nov. 8, 2018 /PRNewswire/ -- Recursion Pharmaceuticals, a biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop ...
Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...
Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...
Tech Times on MSN
Recursive launches Flint AI, free coding model that runs on laptops
Read about Recursive's Flint AI coding model, its laptop-friendly design, coding benchmarks, open-source license, and Eureka Machine technology.
Zacks Investment Research on MSN
Recursion's Q3 earnings beat estimates on Sanofi milestone revenues
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results